Overview

Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder

Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the overall safety and tolerability profile of two dose levels of DVS-233 SR during 6 months of open-label treatment in elderly outpatients with major depressive disorder.
Phase:
N/A
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer